J&J wins FDA approval for facial filler

J&J received FDA approval to market Evolence, the first offering by a major U.S. pharmaceutical manufacturer in the dermal filler market. The injectable collagen, from J&J's new aesthetics group, is a porcine-derived collagen filler recommended for treating facial wrinkles, especially deep facial wrinkles and folds, and will compete with big sellers Juvaderm (Allergan) and Restalyne (Medicis). Success will likely depend on whether consumers prefer a pig-derived product or a synthetic one, as well as the likelihood of consumers to hit the luxury cosmetic bar to drown their sorrows in challenging economic times. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.